{"id":"NCT02651194","sponsor":"AbbVie","briefTitle":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection","officialTitle":"A Single-Arm, Open-Label, Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally-Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (EXPEDITION-4)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12","primaryCompletion":"2016-10","completion":"2017-01","firstPosted":"2016-01-08","resultsPosted":"2017-10-16","lastUpdate":"2017-10-16"},"enrollment":104,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis C Virus (HCV) Infection"],"interventions":[{"type":"DRUG","name":"ABT-493/ABT-530","otherNames":["ABT-493 also known as glecaprevir","ABT-530 also known as pibrentasvir","MAVYRET"]}],"arms":[{"label":"ABT-493/ABT-530","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the efficacy and safety of 12 weeks of treatment with the ABT-493/ABT-530 combination regimen in adults with chronic HCV genotype 1 - 6 infection and chronic severe renal impairment.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)","timeFrame":"12 weeks after the last actual dose of study drug","effectByArm":[{"arm":"ABT-493/ABT-530","deltaMin":98.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["31568620","30977945","30923816","30529905","30012435","29020583"],"seeAlso":["http://rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":25,"n":104},"commonTop":["PRURITUS","FATIGUE","NAUSEA","DIARRHOEA","ASTHENIA"]}}